Brief: Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial
08/02/2024 16:01
Feb 8 (Reuters) - Cadrenal Therapeutics Inc CVKD.O :
* CADRENAL THERAPEUTICS APPOINTS JEFF COLE AS CHIEF
OPERATING
OFFICER IN ADVANCE OF TECARFARIN PHASE 3 PIVOTAL TRIAL
Source text for Eikon: ID:nPn9NddtGa
Further company coverage: CVKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology